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Abstract
Background: Oxidative stress, characterized by an imbalance between the generation reactive oxygen species (ROS) and the capacity of the intrinsic 
antioxidant defense system, may be implicated in the pathogenesis of cardiovascular diseases.  Percutaneous transluminal coronary angioplasty (PCI) 
followed by the implantation coronary stents may be associated with a process of ischemia and reperfusion related injury.  PCI and stent deployment 
induce production of vascular reactive oxygen species (ROS) and reactive nitrogen species (RNS), leading to post-procedural pathophysiological changes, 
including restenosis, stent thrombosis, and endothelial dysfunction.
The aim of the present study was to demonstrate, through the analysis of such parameters as Malondialdehyde (MDA), Superoxide dismutase (SOD) 
and Catalase, those early changes in oxidative stress take place in stable coronary artery disease (CAD) patients undergoing elective PCI with implantation 
of coronary stents.
Material and methods: In this study 120 consecutive chronic stable angina pectoris  patients (mean age 59 ± 0,63 years, 80% male) undergoing PCI 
for management of single and multi -vessel CAD were included.  Malondialdehyde, Superoxide dismutase and Catalase enzymes activity were measured 
before and after the procedure, as well as 24 hours later, then after 1, 3, 6 months. Simvastatin was administered at different doses: group I received – 
20 mg, group II received – 40 mg of simvastatin and group III – 80 mg 12 hours before the angioplasty with stent implantation.
Results: The obtained outcomes indicate that the oxidative stress activity increased in the patients with CAD versus control group.  Traumatic impact 
by expanding stent pressure was observed within 24 hours after angioplasty by raising MDA and lowering SOD and Catalase.
Conclusions: Pleiotropic antioxidant effects of simvastatin administered to patients after revascularization, manifested by abolishing oxidative stress 
(DAM) and raising antioxidant enzymes (SOD, Catalase) in the next steps 1, 3, 6 months after PCI.
Key words: oxidative stress, revascularization, atherosclerosis.
Introduction
Atherosclerosis is a chronic immuno-infl ammatory and 
fi broproliferative disease of the medium and large arteries. 
Th e natural history of atheroma plaque counts three stages – 
initiation, progression and complications. 
Th e initiation stage begins with the changes of homeostat-
ic functions and molecular alterations of vascular endothe-
lial cells triggered by atherogenic stimuli.  Th e progression 
is the result of fi broproliferative response to infl ammation 
and involves accumulation of intimal smooth muscle cells 
(SMCs). SMCs release macromolecules of the extracellular 
matrix forming a collagen-rich network that provides stabil-
ity to the plaque.  Th e atherosclerosis progression frequently 
causes fi brosis and calcium accumulation, wih a stabilizing 
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eff ect on the plaque, meanwhile the neovascularization oc-
curs.  Both processes – fi brosis and certain calcifi cation pat-
terns are currently considered dynamic phenomena that can 
equally express plaque stability, but also its vulnerability.
Th e complications stage or vulnerable, unstable plaque 
has a multifactorial etiology.  Complex biological processes 
such as infl ammation and fi brous head and necrotic lipid 
core remodeling are essential.  Plaque remodeling is a re-
sult of both the matrix synthesis reduction and the increased 
degradation of collagen and elastin [1].
Intravascular view of the vulnerable atheroma plaque. 
Intravascular ultrasound (IVUS) is a conventional method 
used for the assessment of coronary artery atherosclerosis, 
which has the advantage of providing tomographic images 
in real time cross-section.  Th e vulnerability is indicated 
by the eccentric pattern, the presence of ecolucent nucleus, 
positive remodeling, the presence of thrombi, as well as by 
quantitative information like the plaque length and lumen 
narrowing.
Optical coherence tomography (OCT) has the advantage 
of high resolution in ex vivo experiments reaching the sen-
sitivity between 71-96% and the specifi city between 90-98% 
for identifying the plaque morphology.  At patients with PCI, 
the IVUS proved to be superior because it can recognize the 
thin head of the plaque, rupture and thrombi. OCT is the 
only method capable of recognizing eroded plaques.
Th e Spectroscopy uses the fi eld in the vicinity of the in-
frared, is based on the absorption and scattering of light of 
diff erent organic molecules.
Th e Th ermography has the principle of heat production 
by the vulnerable plaque in the presence of infl ammation 
and neovascularization.  Th e main disadvantage is the cool-
ing eff ect produced by the bloodstream.
Noninvasive view of the vulnerable atheroma plaque. 
Multidetector CT angiography is a method that allows the 
study of the characteristics and extension of the intramural 
atherosclerosis, certain vulnerable plaque features identifi -
cation such as the positive remodeling, the increased pro-
portion of non-calcium or mixed components in plaque, 
the stained appearance of calcifi cations, plaque low density. 
However, assessing density of the fi brous plaques versus 
those with a rich content of fat has limitations, as well as thin 
fi brous head plaques identifi cation.
Positron emission tomography is addressed in the fi rst 
line to the identifi cation of the atherosclerosis plaque com-
ponents throughout the arterial tree.  One advantage is the 
reproducibility of assessment that would allow monitoring 
progress under treatment in large arteries.  Th e technique 
has limitations at the coronary artery level due to the intense 
intake of the tracer by the myocardium.
Nuclear magnetic resonance is particularly suitable for 
large arteries, such as carotid arteries.  At present, it is con-
sidered a potential method for evaluating both plaque mor-
phology and composition but new technical performances 
are needed to increase reproducibility, usability for coronary 
atherosclerosis and, of course, determine the clinical predic-
tive value for acute vascular events.  Current literature ma-
kes premature the routine application of nuclear magnetic 
resonance for useful molecular imaging in characterizing 
the vulnerability.
Contrast ultrasound is a method applicable to the cha-
racterization of atheroma plaque due to the use of specifi c 
contrast agents.  Th e small size allows seizure at microvas-
cular level, implicitly in vessels of neoformation from the 
vulnerable plaque [2].
In a series of autopsies with human implants, Inoue et 
al. have reported that signifi cant changes occur in neointima 
as BMS.  Th e arteries that were stented from 2 to 3 years 
showed endothelial coverage with smooth muscle and col-
lagen, rich neointima.  Chronic infl ammation was observed 
and was characterized by macrophages, T cells, and giant cell 
infi ltration.  At the stents implanted over 4 years, smooth 
muscle cells were rare, abundant collagen to lumen and 
foamy macrophages (so-called „neoatherosclerosis”), which 
expressed metalloproteinases.  Th ese data suggest that neo-
intimal formation, which occurs aft er metallic stent implants 
is subject to the same atherosclerotic forces that aff ect the na-
tive vessels and macrophages mediate collagen degradation 
and ultimately could lead to the formation of necrotic core, 
and possible rupture and thrombosis.  Atherosclerosis newly 
formed within the neointimal tissue of the stented segments, 
has been called „neoatherosclerosis”.  It contains the necrotic 
core with cholesterol crystal.  Th e fi brous plaque covering 
the necrotic core is infi ltrated with numerous foamy mac-
rophages [3].
Recently, computerized coherent tomography is able to 
detect the development of new atherosclerosis in stented seg-
ments, at patients alive.  In the register “CVTath stent regis-
try” with a number of 299 autopsies, comprising 406 lesions 
(197 BMS, DES 209 [103 SES and PES 106]) – with implant 
duration over 30 days.  Th e neoatherosclerosis pathological 
criteria were: peri-strut foam macrophages, fi broatheroma, 
thin fi brous atheromatous carcase, rupture with thrombosis. 
Th e neoatherosclerosis incidence was signifi cantly higher at 
the DES (31%) vs. BMS (16%).  Th e average lasting of ne-
oatherosclerosis presence in stent was at the DES vs. BMS 
(420 days vs. 2160).  Th e independent determinant of the 
neoatherosclerosis includes long lasting of implantation and 
type of stent [4].
Another study assessed the neointimal tissue at patients 
treated with DES between 9 months and 2 years of follow-
up.  A total of 76 DES were assessed.  From which 23 with 
SES (Cypher), 20 PES (Taxus), 25 SEZs (Endeavor), 8 EES 
(Xience).  Th is study that used serial OCT suggested that 
intrastent neoatherosclerosis, including conversion to neo-
intima loaded with fat, can progress further during follow-
up aft er implantation of DES. Regardless of DES type, the 
lipid loaded neointima was more frequently detected aft er 
2 years of folow-up compared to 9 months (27.6% vs 14.5%, 
p = 0.009) [5].
W. Gerritsen et al. (2006, 2008) considers DAM as a mar-
ker of global and useful oxidative stress in assessing myocar-
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dial injuries in patients undergoing PCI, including assessing 
eff ectiveness of diff erent technical methods applied for this 
purpose [6, 7].
Th e role of oxidative stress (OS) in cardiovascular patho-
logy is confi rmed by registers from clinical and basic studies 
concerning the development of atherosclerosis, heart disea-
se coronary, congestive heart failure, cardiac arrhythmias, 
hypertension, stroke, etc. [8].
Th e oxidative stress refl ects a status in which the reactive 
oxygen species (ROS) prevail antioxidant defense mechanis-
ms [9]. SRO are involved in a large number of cardiovascular 
diseases including hypertension, atherosclerosis, myocardial 
infarction, and restenosis following angioplasty or by-pass 
[10].  PCI causes increased ROS removal of the aff ected ar-
tery wall place.  Many of these mechanisms contribute to in-
volvement in endothelial function [11].  Th us, the purpose 
of the study was to study the evolution of oxidative stress 
markers at patients exposed to coronary angioplasty.
Material and methods
Th e study selected 120 patients with stable pectoris an-
gina who were treated for myocardial revascularization by 
coronary angioplasty with stent implantation and who re-
ceived lipid-lowering preparation, simvastatin,  according 
to the assigned lot.  In addition to individual anti-ischemic 
treatment was administered Aspirin Clopidogrel (as the 
standard antiplanichetar treatment).  Other classes of prepa-
rations were administered at the discretion of the attending 
physician.
Th e patients were under treatment within the Institute of 
Cardiology during 2012-2014.  Th ey were followed-up for 6 
months with assessment at diff erent stages: stage I – pre PCI, 
stage II – aft er PCI (24 hours), stage III – 1 month, stage IV 
– 6 months.  Group I consisting of 62 patients received 20 mg 
of simvastatin, group II consisting of 26 patients received 40 
mg of simvastatin and group III received 80 mg of simvasta-
tin 12 hours before PCI.
To assess the activity of oxidative stress the following 
markers have been estimated:
1. lipid oxidation product – malondialdehyde (MAD);
2. antioxidant system parameters – superoxide dismutase 
(SOD) and catalase;
Results and discussions
Changes in circulating levels of oxidation products 
(MAD) in both the pre PCI stage and the following ones af-
ter PCI, 1, 3, 6 and 12 months are shown in table 1.
Malondialdehyde as one of the end products of lipid pe-
roxidation, indicates the enabling of  oxidative stress.  Sta-
tistically speaking, DAM data at the initial stage in 3 groups 
were not diff erent (p > 0.05): group I – 11.8 ± 0.99 μM/L, 
group II – 10.87 ± 2.29 μM/L and group III – 15.43 ± 4.21 
μM/L, which reveals elevation against the statistically signifi -
cative baseline.  In all 3 groups of post-PCI, the DAM incre-
ased, showing an oxidative stress activation resulting from 
stent implantation and endothelial injury at coronary level. 
Th us, in group I the DAM level – 16.3 ± 3.49 μM/L, in group 
20.19 ± 5.07 μM/L and group III – 19.71 ± 4.92 μM/L.  Sub-
sequently, the DAM decreased to 8.47 ± 0.86 μM/L in group 
I, in group II – 4.83 ± 0.81 μM/L, in group III 9.62 ± 3.8 
μM/L.  A statistically signifi cant decrease in oxidant marker 
was recorded at the stage of 6 months in group I (7.63 ± 0.87 
μM/L vs 11.8 ± 0.99 μM/L with p < 0.05) and in group III 
(5.47 ± 0.3 μM/L vs 15.43 ± 3.21 μM/L).
Th e catalase is an intracellular enzyme which is a true 
component of antioxidant system. Catalase, at patients with 
atherosclerotic coronary pathology enrolled in the study, de-
monstrates the compromised antioxidant system through its 
Table 1
Malondialdehyde indices and their dynamics at all stages of the study 







80 mg simvastatin PI.II PI,III PII,III
N M m N M m N M m
Pre 43 11.80*** 0.99 17 10.87** 2.29 24 15.43*** 3.21 > 0.05 > 0.05 > 0.05
Post 49 16.30*** 3.49 22 20.19** 5.07 26 19.71*** 4.92 > 0.05 > 0.05 > 0.05
1 month 46 12.47*** 1.66 20 14.70** 3.04 22 12.82** 2.71 > 0.05 > 0.05 > 0.05
3 monts 14 8.47*** 0.86 3 4.83 0.81 5 9.62** 3.8 < 0.05 > 0.05 > 0.05
6 months 19 7.63*** 0.87 5 19.35 9.82 2 5.47** 0.30 > 0.05 < 0.05 > 0.05
pd post > 0.05 > 0.05 > 0.05
pd 1 l > 0.05 > 0.05 > 0.05
pd 3 l > 0.05 > 0.05 > 0.05
pd 6 l < 0.01 0.05 ---
Legend: p d.post – DAM dynamics at post PCI stage versus initial stage; p d.1 l. – DAM dynamics at the 1 month stage versus initial stage; p d 3 
l. – DAM dynamics at the 3 months stage versus initial stage; p d 6 l. – DAM dynamics at the 6 months stage versus initial stage;
* – p < 0.05; ** – p < 0.01; *** – p < 0.001 – statistical signifi cance compared to the baseline.
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low level of statistical signifi cance (p < 0.001) compared to 
the pre PCI and compared to the reference group in all 3 gro-
ups of patients (19.51 ± 1.35 μM/L in group I, 14.23 ± 1.53 
μM/L in group II and 13.56 ± 1.02 sample II μM/L vs. 26.0 
± in group III 0.90μM/L reference).  For the pre PCI stage 
the catalase level was higher in group I (< 0.05) compared 
to group II and III, although patients have been divided into 
groups aimlessly with no certain principles (tab. 2).
Under the simvastatin treatment the catalase level began 
to rise from the post PCI stage even though statistically in-
signifi cant (19.53 ± 1.56 μM/L for group I, 16.38 ± 1.49μM/L 
for group II and 16.46 ± 1.37 μM/L for group III).  Th is incre-
ase continued at next stages.  Th e highest fi gures have been 
recorded at the stage of 6 months for all 3 groups (24.15 ± 1.9 
μM/L, 17.93 ± 4,43 μM/L and 18.7 ± 0.52 μM/L respectively) 
being higher in group I (p I, III < 0.05).
Superoxide dismutase (SOD) is the enzyme that assu-
res the transformation processes of superoxide anion into 
hydrogen peroxide and thus is recognized as an important 
component of the antioxidant system.  Reducing the quan-
tities of SOD compared to baseline denotes a compromised 
antioxidant system and indicates the activation of oxidative 
stress.  Th erefore, the reduction of SOD is associated with 
the elevation of malondialdehyde.  A compromised antioxi-
dant system is attested at the stage before the angioplasty in 
all groups of patients compared to the baseline group, sta-
Table 2 
Catalase indices and their dynamics at all stages of the study








80 mg simvastatin PI.II PI,III PII,III
N M m N M m N M M
Pre 43 19.51*** 1.35 17 14.23*** 1.53 24 13.56*** 1.02 < 0.05 < 0.001 > 0.05
Post 49 19.53*** 1.56 22 16.38*** 1.49 26 16.46*** 1.37 > 0.05 > 0.05 > 0.05
1month 47 19.55*** 1.53 20 15.92*** 1.15 22 13.67*** 1.07 > 0.05 < 0.01 > 0.05
3months 14 21.46* 1.86 3 16.77** 6.43 5 13.06*** 2.18 > 0.05 < 0.05 > 0.05
6months 19 24.15 1.9 5 17.93* 4.43 2 18.70*** 0.52 > 0.05 < 0.05 > 0.05
p d post > 0.05 > 0.05 > 0.05
pd 1l > 0.05 > 0.05 > 0.05
pd 3l > 0.05 > 0.05 > 0.05
pd 6l > 0.05 > 0.05 ---
Legend: p d.post – catalase dynamics at PCI stage versus initial stage; p d.1 l. – catalase dynamics at the 1 month stage versus initial stage; p d 3 l. – 
catalase dynamics at the 3 months stage versus initial stage; p d 6 l. – catalase dynamics at the 6 months stage versus initial stage;
* – p < 0.05; ** – p<0.01; *** – p < 0.001 – statistical signifi cance compared to the baseline.
Table 3
Superoxide dismutase indices and their dynamics at all stages of the study







80 mg simvastatin PI.II PI,III PII,III
N M M N M m N M m
Pre 43 874.04*** 41.74 17 864.26** 77.34 24 878.29** 56.44 >0.05 > 0.05 > 0.05
Post 49 886.82*** 40.22 22 936.11** 45.55 26 911.31** 57.69 >0.05 > 0.05 > 0.05
1month 47 948.35** 35.85 20 976.39 87.86 22 980.51 80.0 >0.05 > 0.05 > 0.05
3months 14 1069.33 80.00 3 1163.05 182.36 5 746.10*** 63.36 >0.05 > 0.05 > 0.05
6months 19 1094.30 61.85 5 981.02 111.79 2 1038.91 151.75 >0.05 > 0.05 > 0.05
pd post > 0.05 > 0.05 > 0.05
pd 1l > 0.05 > 0.05 > 0.05
pd 3l > 0.05 > 0.05 > 0.05
pd 6l 0.05 > 0.05 ---
Legend: p d.post – SOD dynamics at PCI stage versus initial stage; p d.1 l. – SOD dynamics at the 1 month stage versus initial stage; p d 3 l. – SOD 
dynamics at the 3 months stage versus initial stage; p d 6 l. – SOD dynamics at the 6 months stage versus initial stage;  
p < 0.05; ** – p < 0.01; *** – p < 0.001 – statistical significance compared to the baseline.
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tistically signifi cant (p < 0.001): 874.04 ± 41.74 u/c, 864.26 
± 77.34 u/c, 878.29 ± 56.44 u/c against the baseline 1075.28 
±16.49 u/c (tab. 3).
Th e antioxidant system has been activated since the fi rst 
hours aft er PCI, having as impetus the impact provoked to 
the vessel when infl ating the balloon to high pressure and 
stent implantation. Th e data on SOD at the pre PCI stage 
had no signifi cant diff erences among groups.  At subsequent 
stages 1, 3, 6 months were recorded fi gures for SOD.  So at 
6 months stage they reach 1094.3 ± 61.85 u/c for group I, 
981.02 ± 111.79 u/c for group II and 1038.91 ± 151.75 u/c 
for group III, having statistical signifi cance for group I 
(p = 0.05).
Activation of oxidative stress and antioxidant system in-
competence is due to mechanical impact of angioplasty.  In-
dices are modifi ed especially in the fi rst 24 hours.  A cluster 
of pro-infl ammatory cells are connected during the mecha-
nical alteration of the covered coronary artery wall, with ad-
ditional release of reactive oxygen.
Several authors report on compromised antioxidant sys-
tem in cardiovascular diseases, especially in patients with 
ischemic heart disease and diabetes.
DAM is a fi nal product resulting from the breakdown of 
arachidonic acid and polyunsaturated fatty acids by enzyma-
tic or non-enzymatic means.  DAM production by enzyma-
tic processes is well known, but its biological functions and 
dose dependency have not been studied although DAM is 
chemically more stable and with a more permeable membra-
ne than other SRO [13].
Th e catalase is, along with other 2 enzymes (fumarase 
and acetylcholinesterase), one of the most eff ective known 
catalysts, the reactions they catalyze being essential for life. 
Th e enzyme catalyzes a reaction every time it encounters a 
sulfur molecule. Relative speed and orientations of the inter-
acting molecules are important for the reaction.  Th e cata-
lase acts in the conversion of hydrogen peroxide (2H2O2 → 
2H2O + O2) which is a strong oxidizing agent, with a toxic 
character for cells.
Superoxide dismutase is considered the most eff ective 
antioxidant.  Th e importance of SOD is extremely high for 
the protection of our cells, which represent a substantial part 
of the proteins produced by the body.  Defi ciency in SOD/
Catalase is the most notorious nutrient factor in most “in-
fl ammatory” processes. Given the strong link between free 
radicals and many health problems today, supplements that 
increase the activity of SOD/Catalase in the body off er a 
huge potential.
Conclusions
Th e oxidative stress activity is already at the initial sta-
ge compromised, which shows that in patients with stable 
angina pectoris prevail oxidant system indices (DAM) over 
the antioxidants (SOD, Catalase) versus the reference group.
Th e traumatic impact by expanding pressure of the stent 
was observed within 24 hours aft er angioplasty by raising 
DAM and by lowering the SOD and Catalase levels.
Antioxidant pleiotropic eff ects of simvastatin adminis-
tered to patients aft er coronary angioplasty, manifested by 
abolishing oxidative stress (DAM) and raising antioxidants 
indices level (SOD, Catalase) at the next stages 1, 3, 6 months 
aft er PCI.
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